Dr. DeKosky is an internationally recognized leader in Alzheimer's research. Prior to his position at University of Virginia's School of Medicine, he was chair of the department of neurology and director of the Alzheimer's Disease Research Center (ADRC) at the University of Pittsburgh, where he isolated the Pittsburgh B compound (PIB), a plaque-like substance secreted in the brain that allows the clearest scans possible of potential damage from Alzheimer's. His research focuses on differential diagnosis, neuroimaging, genetic risk factors, and the science and clinical care of Alzheimer's, including the pathological and chemical alterations involved with Alzheimer's development. He was also the director of a national multicenter trial assessing the effectiveness of Gingko biloba in delaying the onset of dementia in healthy adults.

Dr. Black's research interests include stroke recovery and vascular cognitive impairment, diagnosis of dementia, and the use of neuroimaging to study brain-behavior relationships. She has published more 350 papers and is actively engaged in clinical trials of stroke and stroke recovery, Alzheimer's, and vascular cognitive impairment. In 2001, she received the Mel Silverman Award for Outstanding Mentorship from the University of Toronto's Institute of Medical Science, and in 2009, the University of Toronto, Department of Medicine Mentorship Award

Dr. Brayne is a medical epidemiologist whose research focuses on longitudinal studies of older people in order to provide more knowledge about aging. Her work includes two large cohort studies, the Cambridge City over 75 Cohort and the MRC/Department of Health Cognitive Function and Ageing Study. These studies are designed to answer questions about biological aspects of aging as well as natural history and policy aspects. Dr. Brayne is involved in epidemiological research about specific neurodegenerative conditions, including Parkinson's disease and early-onset dementias.

Dr. Breteler is principal investigator for neurologic diseases of the Rotterdam Study, a prospective population-based study of frequency and causes of age-related disorders among 15,000 persons older than age 45, and principal investigator of the Rotterdam Scan Study, a population-based neuroimaging study of determinants and clinical consequences of degenerative and cerebrovascular brain changes. In the early 1990s, Dr. Breteler was one of the first epidemiologists to challenge the strict clinical distinction between Alzheimer's and vascular dementia, and to incorporate brain imaging in population-based studies.

Dr. Chaves is a member and current coordinator of the Scientific Department of Cognitive Neurology and Aging of the Brazilian Academy of Neurology and coordinator of the Alzheimer's disease and dementia research group from Universidad Federal do Rio Grande do Sul. She has published more than 50 international papers on the topics of dementia, Alzheimer's disease, cognition and memory.

Dr. Chen has developed comprehensive multi-disciplinary dementia programs and encouraged collaborative research in the Asia-Pacific region and beyond. In addition, he has developed a Trials Unit focusing on stroke and dementia with extensive international collaborations. He is presently responsible for the NUHS Translational Dementia Research Program.

Dr. Kaye directs the Layton Aging and Alzheimer's Disease Center at OHSU and the Portland Veterans Affairs Medical Center. He also directs the Oregon Center for Aging and Technology (ORCATECH). Dr. Kaye's research focuses on the question of why some individuals remain protected from dementia at advanced ages while others succumb to it much earlier. The centerpiece of his studies is the ongoing Oregon Brain Aging Study, established in 1989. He currently leads a large NIH study using technologies to assess seniors in their homes to detect cognitive decline.

Dr. Masters is head of the Alzheimer's Project at the Mental Health Research Institute of Victoria and co-founding scientist of Prana Biotechnology Limited. His research focus is on beta-amyloid and identifying pathways through which environmental and genetic factors can cause Alzheimer's. In 2008, he earned the Lifetime Achievement Award in Alzheimer's Disease Research at the Alzheimer's Association 10th International Conference on Alzheimer's Disease (AAICAD).

Dr. Mittelman has been developing and studying innovative interventions for family caregivers for over two decades. She is principal investigator of an award-winning federally funded landmark study of counseling and support for Alzheimer's caregivers, and is an author of several books and numerous articles in major scientific journals.

Dr. Rockwood has had a longstanding interest in clinical and epidemiological aspects of frailty, dementia and delirium. Dr. Rockwood has published more than 300 peer-reviewed scientific publications and seven books. He holds several CIHR grants, including as principal investigator of the Canada China Collaboration on Aging and Longevity and the Canadian Dementia Knowledge Translation Network. The latter is a national, multicentre project to provide better care for people with dementia by facilitating and carrying out translational research and knowledge translation.

Dr. Scheltens is main clinical and research interests are Alzheimer's disease, vascular dementia, frontotemporal dementia, magnetic resonance imaging, PET imaging and biomarkers. The principal investigator for many studies, including phase 1-3 multicenter clinical trials, he has authored more that 480 peer reviewed papers. Dr. Scheltens chairs the dementia panel of the European Federation of Neurological Societies. He was appointed member of the Royal Academy of Arts and Sciences in 2011. He is member of the editorial boards of Dementia and Geriatric Cognitive Disorders and International Journal of Geriatric Psychiatry, and acts as an ad hoc reviewer of scientific articles for, amongst others, The Lancet; Stroke; Neurology, Annals of Neurology, New England Journal of Medicine, Brain and Science.